Structure Therapeutics (GPCR) Receivables - Other (2025 - 2026)
Structure Therapeutics' (GPCR) quarterly Receivables - Other came in at -$100.0 million in Q1 2026, down 200.0% quarter-over-quarter from $100.0 million in Q4 2025.
Structure Therapeutics (GPCR) Receivables - Other (2025 - 2026) Analysis & Trends
Structure Therapeutics' Receivables - Other history runs 2 years deep, the most recent figure standing at -$100.0 million for Q1 2026.
- On a quarterly basis, Receivables - Other changed N/A year-over-year to -$100.0 million in Q1 2026; TTM through Dec 2025 was $100.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $100.0 million, changed N/A from the prior year.
- Receivables - Other eased to -$100.0 million in Q1 2026 per GPCR's latest filing, from $100.0 million in the prior quarter.
- Across five years, Receivables - Other topped out at $100.0 million in Q4 2025 and bottomed at -$100.0 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Structure Therapeutics | 11.04 Bn | 11.04 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -100.00 Mn |
| Mar 31, 2026 | -100.00 Mn |
| Dec 31, 2025 | 100.00 Mn |
| Dec 31, 2025 | 100.00 Mn |